Literature DB >> 31150825

Outcomes of Uniportal vs Multiportal Video-Assisted Thoracoscopic Lobectomy.

Etienne Bourdages-Pageau1, Arthur Vieira1, Yves Lacasse1, Paula Ugalde Figueroa2.   

Abstract

The optimal number of incisions for video-assisted thoracoscopic surgery (VATS) lobectomy, the standard treatment for early-stage nonsmall cell lung cancer (NSCLC), is still a matter of great debate. To compare single-incision (uniportal) VATS (U-VATS) with traditional multiportal VATS (M-VATS), we retrospectively reviewed the surgical outcomes of a large cohort of patients. Our prospectively maintained institutional database was queried retrospectively. All patients from 2014 to 2017 who underwent VATS lobectomy as the primary procedure for clinical stage I or II NSCLC were identified. A univariate comparison and a propensity-matched analysis incorporating preoperative variables were performed. The incidence of postoperative complications was compared. During the study period, 722 patients underwent VATS lobectomy for early-stage NSCLC, 62% by M-VATS, and 38% by U-VATS. In the univariate analysis, U-VATS performed by an experienced surgeon was associated with decreased intraoperative bleeding and shortened duration of surgery, duration of chest tube drainage, and length of hospital stay as compared with M-VATS (P < 0.001). Mediastinal lymph node dissection and complete resection were accomplished similarly using U-VATS and M-VATS. When the 2 approaches were compared through propensity matching, U-VATS was associated with fewer pneumonias (P = 0.012), as well as decreased intraoperative bleeding (P < 0.001), faster surgery (P < 0.001), shorter duration of chest tube drainage (P = 0.001), and shorter hospital stay (P < 0.001). At our institution, in the hands of an experienced surgeon, U-VATS lobectomy is safe, feasible, and can result in similar short-term outcomes for early-stage NSCLC as compared with M-VATS.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lobectomy; Lung cancer; Single-port; Uniportal; VATS

Mesh:

Year:  2019        PMID: 31150825     DOI: 10.1053/j.semtcvs.2019.05.021

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  7 in total

Review 1.  New Surgical Approaches in the Treatment of Non-Small Cell Lung Cancer.

Authors:  Giye Choe; Rebecca Carr; Daniela Molena
Journal:  Clin Chest Med       Date:  2020-04-16       Impact factor: 2.878

2.  The learning curve of thoracoscopic surgery in a single surgeon and successful implementation of uniportal approach.

Authors:  Hitoshi Igai; Mitsuhiro Kamiyoshihara; Shinya Furusawa; Fumi Ohsawa; Tomohiro Yazawa; Natsumi Matsuura
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

3.  Uniportal versus multiportal video-assisted thoracoscopic anatomical resection for NSCLC: a meta-analysis.

Authors:  Yueren Yan; Qingyuan Huang; Han Han; Yang Zhang; Haiquan Chen
Journal:  J Cardiothorac Surg       Date:  2020-09-09       Impact factor: 1.637

4.  Current role of uniportal video-assisted thoracic surgery for lung cancer treatment.

Authors:  Luciano Bulgarelli Maqueda; Ricardo A J Luengo Falcón; Chiao-Yun Tsai; Alejandro García-Pérez; Anna Minasyan; Diego Gonzalez-Rivas
Journal:  J Clin Transl Res       Date:  2020-09-02

5.  Nonintubated versus intubated "one-stage" preoperative localization and thoracoscopic lung resection.

Authors:  Po-Kuei Hsu; Yi-Ying Lee; Lin-Chi Chuang; Chien-Kun Ting; Mei-Yung Tsou
Journal:  JTCVS Tech       Date:  2021-09-21

Review 6.  Uniportal video-assisted thoracic surgery approach for simultaneous lung cancer and thymic carcinoma: Case report and literature review.

Authors:  Luca Frasca; Giovanni Tacchi; Filippo Longo; Valentina Marziali; Valerio De Peppo; Alessandro Moscardelli; Pierfilippo Crucitti
Journal:  Thorac Cancer       Date:  2021-12-21       Impact factor: 3.500

7.  Uniportal Versus Multiportal Video-Assisted Thoracoscopic Lobectomy for Lung Cancer: An Updated Meta-analysis.

Authors:  Dimitrios E Magouliotis; Maria P Fergadi; Kyriakos Spiliopoulos; Kalliopi Athanassiadi
Journal:  Lung       Date:  2021-01-02       Impact factor: 2.584

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.